Company achieved an important clinical milestone by advancing to the second cohort with a higher 70 mCi dose following positive Safety and Monitoring Committee recommendation. This represents successful dose escalation progression in their lead therapeutic program, demonstrating safety profile advancement and reinforcing confidence in the development pathway.
Company achieved key clinical milestones including completion of Phase 2b enrollment with strong interim efficacy data (90% concordance), positive safety data for RAD 202 with DSMC approval to advance, and initiation of two new FIH trials. However, sentiment is tempered by significant cash burn ($14.9 million in operating outflows) reducing cash reserves by 44% quarter-over-quarter, raising concerns about runway and future funding needs.
The company received a positive DSMC recommendation allowing acceleration of dose escalation in its Phase 1 trial, demonstrating favorable safety profile and on-track progress toward completing Phase 1 by end of 2026. This represents clinical advancement and validation of the therapeutic candidate.
Company achieved primary endpoint in 90% of Phase 2b patients, secured a major manufacturing and distribution partnership with Siemens Healthineers, received FDA Fast Track Designation, and is progressing toward Phase 3 registrational trial with ensured supply chain support.
The company achieved a significant clinical milestone by dosing the first patient in a Phase 1 trial for RAD 402. Preclinical data demonstrated favorable safety and efficacy profiles with strong tumor targeting and minimal off-target exposure. The advancement of a first-in-class radiotherapeutic into human trials represents meaningful progress toward the company's goal of delivering clinical data in 2026.
Articles that tag RADX but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
